Legato Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Legato Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$911K	Buy	+146,065	New	+$631K	0.08%	371

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Legato Capital Management's MRVI Position: Q2 2026 in Review

Legato Capital Management opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 146,065 shares worth $911K. The stake represents 0.08% of the portfolio and ranks #371 among its holdings.

178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Legato Capital Management held 146,065 shares of Maravai LifeSciences worth $911K as of Q2 2026.
Maravai LifeSciences was a new Legato Capital Management position in Q2 2026.
Maravai LifeSciences made up 0.08% of Legato Capital Management's portfolio in Q2 2026, its #371 holding.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.